WA
ABBV icon

Wealthstream Advisors’s AbbVie ABBV Stock Holding History

Wealthstream Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$488K Buy
2,107
+70
+3% +$14.3K 0.07% 90
2025
Q2 		$378K Buy
2,037
+130
+7% +$24.2K 0.06% 105
2025
Q1 		$399K Sell
1,907
-43
-2% -$8.36K 0.07% 88
2024
Q4 		$346K Sell
1,950
-4
-0.2% -$735 0.06% 98
2024
Q3 		$386K Buy
1,954
+56
+3% +$10.5K 0.07% 85
2024
Q2 		$325K Buy
1,898
+21
+1% +$3.48K 0.12% 89
2024
Q1 		$342K Sell
1,877
-1,632
-47% -$281K 0.13% 90
2023
Q4 		$544K Buy
3,509
+1,609
+85% +$235K 0.22% 63
2023
Q3 		$283K Buy
1,900
+103
+6% +$15.1K 0.15% 79
2023
Q2 		$242K Buy
+1,797
New +$264K 0.13% 86
2023
Q1 		– Sell
-1,252
Closed -$202K – 79
2022
Q4 		$202K Buy
+1,252
New +$192K 0.13% 71
2022
Q2 		– Sell
-1,653
Closed -$268K – 70
2022
Q1 		$268K Buy
1,653
+82
+5% +$11.9K 0.23% 56
2021
Q4 		$213K Buy
+1,571
New +$186K 0.18% 64

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wealthstream Advisors's ABBV Position: Q3 2025 in Review

Wealthstream Advisors increased its AbbVie (ABBV) stake by 3.4% in Q3 2025, buying an estimated $14.3K and bringing the position to 2,107 shares worth $488K. The position accounts for 0.07% of the portfolio, ranked #90.

Wealthstream Advisors first reported a position in ABBV in Q4 2021 and has held it in 13 quarters since. The position peaked at $544K in Q4 2023. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Wealthstream Advisors held 2,107 shares of AbbVie worth $488K as of Q3 2025.
  • Wealthstream Advisors bought 70 AbbVie shares in Q3 2025, an estimated $14.3K.
  • AbbVie made up 0.07% of Wealthstream Advisors's portfolio in Q3 2025, its #90 holding.
  • Wealthstream Advisors first reported a position in AbbVie in Q4 2021 and has held it in 13 quarters since.
  • Wealthstream Advisors's AbbVie position peaked at $544K in Q4 2023.
  • 3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Wealthstream Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.